Amedica (AMDA) Hits New 12-Month High and Low at $1.32

Amedica Co. (NASDAQ:AMDA) reached a new 52-week high and low during mid-day trading on Monday . The stock traded as low as $1.32 and last traded at $1.36, with a volume of 103344 shares traded. The stock had previously closed at $1.52.

AMDA has been the topic of several recent research reports. Maxim Group restated a “hold” rating on shares of Amedica in a research report on Tuesday, March 6th. ValuEngine upgraded Amedica from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $4.67, a PE ratio of -0.10 and a beta of -1.12.

An institutional investor recently raised its position in Amedica stock. Vanguard Group Inc. increased its holdings in Amedica Co. (NASDAQ:AMDA) by 7.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 595,866 shares of the medical equipment provider’s stock after buying an additional 39,603 shares during the period. Vanguard Group Inc. owned 2.26% of Amedica worth $226,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amedica (AMDA) Hits New 12-Month High and Low at $1.32” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

Amedica Company Profile

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with's FREE daily email newsletter.

Leave a Reply